Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres










Base de données
Gamme d'année
2.
Vet Rec ; 178(4): 95, 2016 Jan 23.
Article de Anglais | MEDLINE | ID: mdl-26733051

RÉSUMÉ

The purpose of this study was to further evaluate and validate two commercially available equine arteritis virus (EAV) competitive ELISAs (original and enhanced cELISAs) using archived equine sera from experimentally inoculated animals and field sera submitted for laboratory diagnosis. First, the original and subsequently enhanced cELISAs were compared with the virus neutralisation test (VNT) using a panel of archived serum samples from experimentally inoculated animals. Then, the enhanced cELISA was compared with the VNT using a large panel of archived serum samples. The total number of equine sera tested was 3255, which included sera against 25 different EAV strains. The study confirmed that the enhanced cELISA was more sensitive than the original cELISA. Based on testing sera from experimentally inoculated animals and field sera, the enhanced cELISA had an estimated sensitivity (98.9 percent and 99.6 percent, respectively) and specificity (98.3 percent and 98.7 percent, respectively). The currently marketed enhanced VMRD EAV antibody cELISA test kit (VMRD Inc., Pullman, Washington, USA) has high sensitivity and specificity relative to the VNT. Based on the findings of this study, the authors would propose that the enhanced cELISA should be considered as an alternative approved method to the VNT for the detection of antibodies to EAV.


Sujet(s)
Anticorps antiviraux/sang , Infections à artérivirus/médecine vétérinaire , Test ELISA/médecine vétérinaire , Equartevirus/immunologie , Maladies des chevaux/diagnostic , Animaux , Infections à artérivirus/diagnostic , Test ELISA/méthodes , Maladies des chevaux/virologie , Equus caballus , Tests de neutralisation/médecine vétérinaire , Sensibilité et spécificité
3.
J Ethnopharmacol ; 100(1-2): 180-6, 2005 Aug 22.
Article de Anglais | MEDLINE | ID: mdl-15950418

RÉSUMÉ

Hepatic stellate cells (HSC) play a central role in hepatic fibrosis and compounds that promote apoptosis in HSC may have anti-fibrotic potentials. Herbal medicine has long been used in chronic liver disease but there is little scientific evidence for their actions. The present study investigated the effects of 14 commonly used herbs on cellular proliferation and apoptosis of a rat hepatic stellate cell line, HSC-T6 and the underlying mechanism of herb-induced apoptosis. HSC-T6 cell were incubated with herbal extracts and their proliferation was assessed by colorimetric assay. Apoptosis was measured and confirmed by flow cytometry, terminal transferase uridyl nick end labeling (TUNEL) assay and morphological features in hematoxylin and eosin staining. Apoptotic pathways involving Fas receptor and Bcl-2 family were investigated by Western blot. Five herbs, namely Angelica sinensis (AS), Carthamus tinctorius (CT), Ligusticum chuanxiong (LC), Salvia miltiorrhiza (SM) and Stephania tetrandra (ST) demonstrated both anti-proliferative and pro-apoptotic activities in HSC-T6. The highest potency was detected in SM and ST with 51.63 and 44.52% of HSC-T6 showing apoptotic changes, respectively. This was associated with upregulation of Fas and Bax and down-regulation of Bcl-xL in HSC. Fas ligand and Bcl2 expressions remained unchanged. The potential anti-fibrotic effect of herbal medicine warrants further evaluation.


Sujet(s)
Apoptose/effets des médicaments et des substances chimiques , Prolifération cellulaire/effets des médicaments et des substances chimiques , Médicaments issus de plantes chinoises/pharmacologie , Hépatocytes/effets des médicaments et des substances chimiques , Animaux , Lignée cellulaire , Fragmentation de l'ADN , Relation dose-effet des médicaments , Rats
4.
J Infect Dis ; 144(1): 55-60, 1981 Jul.
Article de Anglais | MEDLINE | ID: mdl-6267143

RÉSUMÉ

A stump-tailed monkey, newly caught and without antibody to hepatitis B virus (HAV), was successfully infected with human HAV. The following alterations were observed in the monkey's functions: (1) elevation in activities of serum glutamic pyruvic transaminase, lactate dehydrogenase, and its type 5 isoenzyme (electrophoretically the fastest moving); (2) development of antibody to HAV; and (3) shedding of HAV antigen in feces. The virus isolated from the monkey, designated the Hangzhou A-1A strain of HAV, was serially transmitted to two other stump-tailed monkeys. Thus, the stump-tailed monkey (Macaca speciosa) is susceptible to infection with human HAV.


Sujet(s)
Hépatite A/transmission , Animaux , Anticorps antiviraux/analyse , Prédisposition aux maladies , Hépatite A/médecine vétérinaire , Hepatovirus/immunologie , Humains , Isoenzymes , L-Lactate dehydrogenase/métabolisme , Macaca/microbiologie , Maladies des singes , Transaminases/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...